Clinical Trials in Depth
Clinical trials Clinical trials: Clinical research is at the heart of all medical advances, identifying new ways to prevent, detect or treat disease.
Acute Myeloid Leukemia (AML)
Eunice S. Wang, MD, on FLT3-Mutated AML: Gilteritinib and Azacitidine for Intensive Induction Chemotherapy–Ineligible Patients
Original Publication Date
Article Source
External Web Content
Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discusses phase III results showing that gilteritinib and azacitidine led to significantly higher composite complete response rates in patients with newly diagnosed FLT3-mutant acute myeloid leukemia who are…
ASH 2021 Recap: Multi Omics Sheds New Light on Malignant Transformation from Myeloproliferative Neoplasm to AML
Original Publication Date
Article Source
External Web Content
Link above leads to podcast recording.
Women With AML Have Worse Outcomes With Gemtuzumab Ozogamicin
Original Publication Date
Article Source
External Web Content
Combination gemtuzumab ozogamicin (GO) and cytarabine is no more effective than standard chemotherapy for older adults with previously untreated, standard-risk acute myeloid leukemia (AML), a phase 2/3 trial suggests. In fact, GO plus cytarabine was associated with worse event…
Dale Schaar, MD, PhD
Institution
Rutgers Cancer Institute of New Jersey
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Eloy Roman, MD
Institution
Lakes Research
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Adrienne Phillips, MD, MPH
Institution
Weill Cornell Medical College
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pure Red Cell Aplasia (PRCA)
Richard Lin, MD, PhD
Institution
Memorial Sloan Kettering Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Celalettin Ustun, MD
Institution
Rush University
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Dr. Jason Mendler
Institution
Wilmot Cancer Center
Physician Status
available for consultation
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Chronic Myelomonocytic Leukaemia (CMML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
Jason Harold Mendler, MD, PhD, Assistant Professor of Oncology, received his bachelor's degree, Summa Cum Laude, from Washington University in St. Louis, Missouri. He then went on to earn his PhD in Genetics and his medical degree at the University of Rochester School of Medicine and Dentistry in Rochester, New York. Prior to joining Wilmot Cancer Center, Dr. Mendler completed his residency at and served as chief resident of the University of Rochester Medical Center, Department of Medicine. Most recently, he completed a clinical fellowship in oncology at Ohio State University Medical Center